N/A N=60 Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)
Popliteal Artery Aneurysm
Primary: Number of Subjects With Primary Patency at 12 Months — 40; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=192 Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial
Abdominal Aortic Aneurysm
Primary: Treatment Success as Defined as the Composite of Procedural Technical Success, Absence of Vascular Complications, and Absence of Major Adverse Events as Determined by…
Phase 4 N=259 GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure — 9; 31 participants — p=<0.001
N/A N=233 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries
Peripheral Arterial Disease
Primary: Efficacy - Number of Participants With Freedom From MALE at 6 Months and POD at 30 Days — 200 Participants
N/A N=25 Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
N/A N=45 Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
N/A N=358 Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
N/A N=28 Ankle-foot Orthoses for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units
Phase 2 N=224 AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=9 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
N/A N=401 Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
Abdominal Aortic Aneurysm · Iliac Aneurysm · Internal Iliac Aneurysm
Primary: Freedom From Aneurysm Rupture — 0 Participants
N/A N=300 Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon
Peripheral Arterial Disease
Primary: Patency at 12 Month Post-procedure — 53; 135 Participants
Phase 2 N=35 Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms
Aortic Aneurysm, Abdominal
Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=171 Multi-center Study for Stent Graft System for Peripheral Artery
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
N/A N=213 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
Peripheral Artery Disease
Primary: Efficacy - Number of Subjects That Met Primary Patency Criteria at 12 Months — 120 Participants
N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
N/A N=155 The Pivotal Study of the Aptus Endovascular AAA Repair System
Abdominal Aortic Aneurysms (AAA)
Primary: Effectiveness: Composite Success Rate — 4 participants
N/A N=44 Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Number of Subjects With Proximal Type I Endoleak — 2 Participants
N/A N=141 Absolute Pro® MOMENTUM™
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 0.0; 0.0; 0.0 percentage of participants
N/A N=33 Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
N/A N=108 Pipeline for Uncoilable or Failed Aneurysms
Intracranial Aneurysm
Primary: Number of Participants With the Occurrence of Major Ipsilateral Stroke or Neurologic Death and Occurrence of Ipsilateral Stroke or Neurologic Death. — 6; 10 Participants…
N/A N=287 Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis
Peripheral Vascular Diseases · Claudication
Primary: Primary Patency — 67.7 Percentage of participants with data
N/A N=19 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
N/A N=20 Geniculate Artery Embolization for the Treatment of Knee Pain
Osteoarthritis Of Knee
Primary: Patient Function (Units on a Scale) — 31 units on a scale
N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
Phase 4 N=881 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)
Aortic Aneurysm
Primary: All-cause Mortality — 146; 146 participants — p=0.81